Pexidartinib clinical trials
Also written PLX3397.
How each study uses pexidartinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the pexidartinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 2 Aug 2019 · TURALIO · NDA 211810 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
27 studies that test it; most in 2015 (6)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 3 |
| 2013 | 2 |
| 2015 | 6 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 20 · Other 7
Daiichi Sankyo (15) · Daiichi Sankyo Co., Ltd. (4) · Centre Leon Berard (1) · The Christie NHS Foundation Trust (1) · Barbara Ann Karmanos Cancer Institute (1) · Hope Rugo, MD (1) · National Cancer Institute (NCI) (1) · QuantumLeap Healthcare Collaborative (1)
Often tested with
Tested in the same studies.
Durvalumab (2) · Antiandrogen Therapy (1) · Trastuzumab (1) · Ganitumab (1) · Ado-Trastuzumab Emtansine (1) · Pertuzumab (1) · STA 9090 (1) · Veliparib (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test pexidartinib.
- Dec 2026Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...Phase 1 · National Cancer Institute (NCI)
Studies
Open first, then newest update. How each study uses pexidartinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 27
- Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...RecruitingPhase 1National Cancer Institute (NCI)NCT02390752Written as TURALIO(R)How we know
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingPhase 2QuantumLeap Healthcare CollaborativeNCT01042379Written as PLX3397How we know
- A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCTActive, not recruitingPhase 3Daiichi Sankyo Co., Ltd.NCT04488822Written as PexidartinibHow we know
- A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in JapanCompletedPhase 2Daiichi Sankyo Co., Ltd.NCT04703322Written as PexidartinibHow we know
- A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated MelanomaCompletedNot applicableDaiichi Sankyo Co., Ltd.NCT02975700Written as PLX3397How we know
- PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath TumorsTerminatedPhase 1/2Gulam ManjiNCT02584647Written as PLX3397How we know
- Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With PexidartinibCompletedPhase 4Daiichi SankyoNCT04526704Written as PexidartinibHow we know
- Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)CompletedPhase 3Daiichi SankyoNCT02371369Written as PexidartinibHow we know
- Study of Pexidartinib in Asian Subjects With Advanced Solid TumorsCompletedPhase 1Daiichi Sankyo Co., Ltd.NCT02734433Written as PexidartinibHow we know
- Safety Study of PLX108-01 in Patients With Solid TumorsCompletedPhase 1Daiichi SankyoNCT01004861Written as PLX3397How we know
- Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal CancersCompletedPhase 1Centre Leon BerardNCT02777710Written as PexidartinibHow we know
- PLX3397 KIT in Acral aNd mucOsal MelanomaCompletedPhase 2The Christie NHS Foundation TrustNCT02071940Written as PLX3397How we know
- Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy ParticipantsCompletedEarly Phase 1Daiichi SankyoNCT04223635Written as PexidartinibHow we know
- Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)CompletedPhase 1Daiichi SankyoNCT03291288Written as PexidartinibHow we know
- PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate CancerCompletedPhase 1Barbara Ann Karmanos Cancer InstituteNCT02472275Written as Multitargeted Tyrosine Kinase Inhibitor PLX3397How we know
- Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast CancerCompletedPhase 1/2Hope Rugo, MDNCT01596751Written as PLX3397How we know
- Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid TumorsCompletedPhase 1Daiichi SankyoNCT01525602Written as PLX3397How we know
- Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin LymphomaCompletedPhase 2Daiichi SankyoNCT01217229Written as PLX3397How we know
- A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed GlioblastomaCompletedPhase 1/2Daiichi SankyoNCT01790503Written as PLX3397How we know
- A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF MelanomaTerminatedPhase 1Daiichi SankyoNCT01826448Written as PLX3397How we know
See all 27 studies that test pexidartinib →
Given beside what is tested · 2 — pexidartinib is usual care or a partner of the new treatment
- CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid TumorsCompletedPhase 1/2Cogent Biosciences, Inc.NCT02401815Written as PexidartinibHow we know
- A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)CompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT03158103Written as PexidartinibHow we know
Codes
What other systems call pexidartinib · ClinicalTrials.gg INT000290
- MeSH (NLM) C000600259pexidartinibOne source NLM
- UNII (FDA) 6783M2LV5XPEXIDARTINIBConfirmed FDA, NLM, Wikidata
- RxNorm 2183102One source FDA
- Wikidata Q25100640pexidartinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C88303PexidartinibOne source FDA
- DrugBank DB12978One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000600259 | pexidartinib | One source NLM |
| UNII (FDA) | 6783M2LV5X | PEXIDARTINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2183102 | — | One source FDA |
| Wikidata | Q25100640 | pexidartinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C88303 | Pexidartinib | One source FDA |
| DrugBank | DB12978 | — | One source Wikidata |
Also registered as pexidartinib hydrochloride (UNII YS6WAI3XN7 · RxNorm 2183103).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.